Use of dried capillary blood sampling for islet autoantibody screening in relatives: A feasibility study

TrialNet Study Group

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Islet autoantibody testing provides the basis for assessment of risk of progression to type 1 diabetes. We set out to determine the feasibility and acceptability of dried capillary blood spot-based screening to identify islet autoantibody-positive relatives potentially eligible for inclusion in prevention trials. Materials and Methods: Dried blood spot (DBS) and venous samples were collected from 229 relatives participating in the TrialNet Pathway to Prevention Study. Both samples were tested for glutamic acid decarboxylase, islet antigen 2, and zinc transporter 8 autoantibodies, and venous samples were additionally tested for insulin autoantibodies and islet cell antibodies. We defined multiple autoantibody positive as two or more autoantibodies in venous serum and DBS screen positive if one or more autoantibodies were detected. Participant questionnaires compared the sample collection methods. Results: Of 44 relatives who were multiple autoantibody positive in venous samples, 42 (95.5%) were DBS screen positive, and DBS accurately detected 145 of 147 autoantibody-negative relatives (98.6%). Capillary blood sampling was perceived as more painful than venous blood draw, but 60% of participants would prefer initial screening using home fingerstick with clinic visits only required if autoantibodies were found. Conclusions: Capillary blood sampling could facilitate screening for type 1 diabetes prevention studies.

Original languageEnglish (US)
Pages (from-to)867-871
Number of pages5
JournalDiabetes Technology and Therapeutics
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Feasibility Studies
Autoantibodies
Type 1 Diabetes Mellitus
Dried Blood Spot Testing
Glutamate Decarboxylase
Ambulatory Care
Insulin
Antigens

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

Use of dried capillary blood sampling for islet autoantibody screening in relatives : A feasibility study. / TrialNet Study Group.

In: Diabetes Technology and Therapeutics, Vol. 17, No. 12, 01.12.2015, p. 867-871.

Research output: Contribution to journalArticle

@article{edecf0b45e9f4b7f93fa02d3c7a0be75,
title = "Use of dried capillary blood sampling for islet autoantibody screening in relatives: A feasibility study",
abstract = "Background: Islet autoantibody testing provides the basis for assessment of risk of progression to type 1 diabetes. We set out to determine the feasibility and acceptability of dried capillary blood spot-based screening to identify islet autoantibody-positive relatives potentially eligible for inclusion in prevention trials. Materials and Methods: Dried blood spot (DBS) and venous samples were collected from 229 relatives participating in the TrialNet Pathway to Prevention Study. Both samples were tested for glutamic acid decarboxylase, islet antigen 2, and zinc transporter 8 autoantibodies, and venous samples were additionally tested for insulin autoantibodies and islet cell antibodies. We defined multiple autoantibody positive as two or more autoantibodies in venous serum and DBS screen positive if one or more autoantibodies were detected. Participant questionnaires compared the sample collection methods. Results: Of 44 relatives who were multiple autoantibody positive in venous samples, 42 (95.5{\%}) were DBS screen positive, and DBS accurately detected 145 of 147 autoantibody-negative relatives (98.6{\%}). Capillary blood sampling was perceived as more painful than venous blood draw, but 60{\%} of participants would prefer initial screening using home fingerstick with clinic visits only required if autoantibodies were found. Conclusions: Capillary blood sampling could facilitate screening for type 1 diabetes prevention studies.",
author = "{TrialNet Study Group} and Bingley, {Polly J.} and Lisa Rafkin and Della Matheson and Steck, {Andrea K.} and Liping Yu and Courtney Henderson and Beam, {Craig A.} and Boulware, {David C.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1089/dia.2015.0133",
language = "English (US)",
volume = "17",
pages = "867--871",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Use of dried capillary blood sampling for islet autoantibody screening in relatives

T2 - A feasibility study

AU - TrialNet Study Group

AU - Bingley, Polly J.

AU - Rafkin, Lisa

AU - Matheson, Della

AU - Steck, Andrea K.

AU - Yu, Liping

AU - Henderson, Courtney

AU - Beam, Craig A.

AU - Boulware, David C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Islet autoantibody testing provides the basis for assessment of risk of progression to type 1 diabetes. We set out to determine the feasibility and acceptability of dried capillary blood spot-based screening to identify islet autoantibody-positive relatives potentially eligible for inclusion in prevention trials. Materials and Methods: Dried blood spot (DBS) and venous samples were collected from 229 relatives participating in the TrialNet Pathway to Prevention Study. Both samples were tested for glutamic acid decarboxylase, islet antigen 2, and zinc transporter 8 autoantibodies, and venous samples were additionally tested for insulin autoantibodies and islet cell antibodies. We defined multiple autoantibody positive as two or more autoantibodies in venous serum and DBS screen positive if one or more autoantibodies were detected. Participant questionnaires compared the sample collection methods. Results: Of 44 relatives who were multiple autoantibody positive in venous samples, 42 (95.5%) were DBS screen positive, and DBS accurately detected 145 of 147 autoantibody-negative relatives (98.6%). Capillary blood sampling was perceived as more painful than venous blood draw, but 60% of participants would prefer initial screening using home fingerstick with clinic visits only required if autoantibodies were found. Conclusions: Capillary blood sampling could facilitate screening for type 1 diabetes prevention studies.

AB - Background: Islet autoantibody testing provides the basis for assessment of risk of progression to type 1 diabetes. We set out to determine the feasibility and acceptability of dried capillary blood spot-based screening to identify islet autoantibody-positive relatives potentially eligible for inclusion in prevention trials. Materials and Methods: Dried blood spot (DBS) and venous samples were collected from 229 relatives participating in the TrialNet Pathway to Prevention Study. Both samples were tested for glutamic acid decarboxylase, islet antigen 2, and zinc transporter 8 autoantibodies, and venous samples were additionally tested for insulin autoantibodies and islet cell antibodies. We defined multiple autoantibody positive as two or more autoantibodies in venous serum and DBS screen positive if one or more autoantibodies were detected. Participant questionnaires compared the sample collection methods. Results: Of 44 relatives who were multiple autoantibody positive in venous samples, 42 (95.5%) were DBS screen positive, and DBS accurately detected 145 of 147 autoantibody-negative relatives (98.6%). Capillary blood sampling was perceived as more painful than venous blood draw, but 60% of participants would prefer initial screening using home fingerstick with clinic visits only required if autoantibodies were found. Conclusions: Capillary blood sampling could facilitate screening for type 1 diabetes prevention studies.

UR - http://www.scopus.com/inward/record.url?scp=84948765929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948765929&partnerID=8YFLogxK

U2 - 10.1089/dia.2015.0133

DO - 10.1089/dia.2015.0133

M3 - Article

C2 - 26375197

AN - SCOPUS:84948765929

VL - 17

SP - 867

EP - 871

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 12

ER -